Comprehensive Review: Mavacamten and Aficamten in Hypertrophic Cardiomyopathy

Comprehensive Review: Mavacamten and Aficamten in Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy (HCM) is the most common monogenic heart disease, with an estimated prevalence of 1:600 in the general population, and is associated with significant morbidity. HCM is characterized by left ventricular hypertrophy and interventricular septal thickening due to sarcomere pr...

Full description

Saved in:

Bibliographic Details
Main Authors:	Helin Savsin, Tomasz Tokarek
Format:	Article
Language:	English
Published:	MDPI AG 2025-07-01
Series:	Biomedicines
Subjects:	mavacamten aficamten cardiomyopathy cardiac myosin inhibitors disease-modifying therapy left ventricular hypertrophy
Online Access:	https://www.mdpi.com/2227-9059/13/7/1619
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Safety and Efficacy of Mavacamten and Aficamten in Patients With Hypertrophic Cardiomyopathy
by: Bryton J. Davis, et al.
Published: (2025-03-01)

Obstructive hypertrophic cardiomyopathy: from genetic insights to a multimodal therapeutic approach with mavacamten, aficamten, and beyond
by: Khadija Sarwer, et al.
Published: (2024-12-01)

Dosing and Safety Profile of Aficamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA‐HCM
by: Caroline J. Coats, et al.
Published: (2024-08-01)

Cardiac myosin inhibitors: Efficacy, safety and future directions of aficamten in hypertrophic obstructive cardiomyopathy
by: Ikponmwosa Jude Ogieuhi, et al.
Published: (2025-06-01)

The effect of mavacamten on echocardiographic parameters, cardiac function and biomarkers in hypertrophic cardiomyopathy patients, a systematic review and meta-analysis
by: Zina Otmani, et al.
Published: (2025-07-01)

Integrative Approaches in the Management of Hypertrophic Cardiomyopathy: A Comprehensive Review of Current Therapeutic Modalities
by: Marco Maria Dicorato, et al.
Published: (2025-05-01)

Hypertrophic Cardiomyopathy with Special Focus on Mavacamten and Its Future in Cardiology
by: Ewelina Młynarska, et al.
Published: (2024-11-01)

Mavacamten in real‐life practice: Initial experience at a hypertrophic cardiomyopathy centre
by: Zaid Abood, et al.
Published: (2025-02-01)

Mavacamten for Obstructive Hypertrophic Cardiomyopathy: Rationale for Clinically Guided Dose Titration to Optimize Individual Response
by: Anjali T. Owens, et al.
Published: (2024-09-01)

Temporal Patterns of Holter-Detected Arrhythmias in Hypertrophic Cardiomyopathy Patients Treated with Mavacamten
by: Amro Badr, et al.
Published: (2025-04-01)

Effect of Mavacamten on Echocardiographic Features in Chinese Patients with Obstructive Hypertrophic Cardiomyopathy: Results from the EXPLORER-CN Study
by: Zhuang Tian, et al.
Published: (2025-04-01)

Mavacamten
by: Matthew W. Martinez, MD, et al.
Published: (2025-01-01)

British Society of Echocardiography guideline for the transthoracic echocardiographic assessment of adult patients with obstructive hypertrophic cardiomyopathy receiving myosin-inhibitor therapy
by: Clare M. Culshaw, et al.
Published: (2025-06-01)

Recent Advances in Novel Modulators for Cardiac Myosin Disorders
by: Hancheng Wang, et al.

An ALPK3 truncation variant causing autosomal dominant hypertrophic cardiomyopathy is partially rescued by mavacamten
by: Lisa Leinhos, et al.
Published: (2025-03-01)

Eighteen‐Month Real‐World Experience Using Mavacamten for Treatment of Obstructive Hypertrophic Cardiomyopathy in a Racially Diverse Population
by: Diego Ramonfaur, et al.
Published: (2024-08-01)

Comprehensive plasma metabolomics profiling develops diagnostic biomarkers of obstructive hypertrophic cardiomyopathy
by: Hao Cui, et al.
Published: (2025-04-01)

The Role of Cardiac Magnetic Resonance Imaging in the Management of Hypertrophic Cardiomyopathy
by: Luca Pugliese, et al.
Published: (2025-05-01)

Clinical manifestation and outcomes of children with hypertrophic cardiomyopathy in Kosovo
by: Ramush A Bejiqi, et al.
Published: (2020-04-01)

Atrial remodelling and dysfunction in hypertrophic cardiomyopathy: prognostic role and therapeutic target
by: Chiara Piazzai, et al.
Published: (2025-07-01)

DIABETIC CARDIOMYOPATHY. RESISTIN: A CONTROL OF A MYOCARDIAL HYPERTROPHY
by: An. A. Aleksandrov, et al.
Published: (2015-09-01)

Identification of candidate cardiomyopathy modifier genes through genome sequencing and RNA profiling
by: Malene E. Lindholm, et al.
Published: (2025-07-01)

Diagnostic Challenges and Management of Hypertrophic Cardiomyopathy with Left Ventricular Outflow Tract Obstruction in a Patient with Hypertension
by: Nina Marta Kubikowska, et al.
Published: (2025-04-01)

ASSOCIATIONS BETWEEN CLINICAL COURSE, LEFT VENTRICULAR HYPERTROPHY SEVERITY AND ACE GENE I/D POLYMORPHISM IN PATIENTS WITH HYPERTROPHIC CARDIOMYOPATHY AND HYPERTENSIVE HEART
by: M. D. Smirnova, et al.
Published: (2009-04-01)

Left ventricular septal convexity in differentiating hypertrophic cardiomyopathy from hypertensive heart disease – a cardiac magnetic resonance study
by: Mika Tarkiainen, et al.
Published: (2025-08-01)

Prevalence and characteristics of transthyretin amyloid cardiomyopathy in hypertrophic cardiomyopathy
by: Pablo Garcia‐Pavia, et al.
Published: (2024-12-01)

The role of cardiac MRI in risk stratification for sudden cardiac death in patients with hypertrophic cardiomyopathy
by: M. S. Ishchenko, et al.
Published: (2024-05-01)

Atrial Fibrillation in Hypertrophic Cardiomyopathy
by: G. A. Ignatenko, et al.
Published: (2021-05-01)

Advancements in the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: A Comprehensive Review
by: Randeep Gill, et al.
Published: (2024-09-01)

The challenges in diagnosing hypertrophic cardiomyopathy in the presence of arterial hypertension: a clinical case
by: O. O. Khaniukov, et al.
Published: (2024-07-01)

Editorial: State-of-the-art muscle physiology research: from single molecules and cells to living organisms
by: Norio Fukuda, et al.
Published: (2025-06-01)

Hypertrophic Obstructive Cardiomyopathy Associated with Moderate Aortic Stenosis in Symptomatic 75-Year-Old Female: A Case Report
by: Abdulgani Abonowara
Published: (2023-01-01)

Microvascular dysfunction causing myocardial ischemia in obstructive hypertrophic cardiomyopathy
by: Nonthikorn Theerasuwipakorn, MD, MSc, et al.
Published: (2025-04-01)

Obstructive Hypertrophic Cardiomyopathy and Aortic Stenosis With High Surgical Risk
by: Omar M. Abdelfattah, MD, et al.
Published: (2025-07-01)

Contrast Enhanced Echocardiography-Controlled Alcohol Septal Ablation for Hypertrophic Cardiomyopathy with Left Ventricular Outflow Tract Obstruction
by: I. E. Nikolaeva, et al.
Published: (2019-07-01)

Cryo-EM structures of cardiac muscle α-actin mutants M305L and A331P give insights into the structural mechanisms of hypertrophic cardiomyopathy
by: Hsiang-Ling Huang, et al.
Published: (2024-12-01)

<i>MYBPC3</i>-associated cardiomyopathy: features of the course and prospects for specific therapy
by: D. A. Nefedova, et al.
Published: (2025-02-01)

Apical hypertrophic cardiomyopathy: contemporary view on the prevalence, clinical profile, diagnostic and treatmen (review of literature)
by: A. A. Streltsova, et al.
Published: (2021-10-01)

Hypertrophic cardiomyopathy occurred after successful surgical correction of supravalvular aortic stenosis: a case report of Williams–Beuren syndrome
by: Hongxiao Yu, et al.
Published: (2025-08-01)

LEFT VENTRICULAR WALL THICKNESS AND AUTONOMIC REGULATION IN PATIENTS WITH HYPERTROPHIC CARDIOMYOPATHY
by: O. Allaberganov, et al.
Published: (2011-10-01)